Development of methodology for conducting clinical trials in frontotemporal lobar degeneration

Brain

Volumn 131, Issue 11, 2008, Pages 2957-2968

  Knopman, David S ^a,g   Kramer, Joel H ^b   Boeve, Bradley F ^a   Caselli, Richard J ^c   Graff Radford, Neill R ^d   Mendez, Mario F ^e   Miller, Bruce L ^b   Mercaldo, Nathaniel ^f  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MAYO CLINIC   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g Mayo Clinic   (United States)

Author keywords

Clinical trials; Frontotemporal dementia; Neuropsychology

Indexed keywords

ADULT; AGED; ARTICLE; BRAIN ATROPHY; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COGNITION; FEASIBILITY STUDY; FEMALE; FOLLOW UP; FRONTAL BEHAVIOR INVENTORY; FRONTAL CORTEX; FRONTOTEMPORAL DEMENTIA; FRONTOTEMPORAL LOBAR DEGENERATION; FRONTOTEMPORAL LOBAR DEGENERATION MODIFIED CLINICAL DEMENTIA RATING; HUMAN; INSULA; LANGUAGE; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; NERVE DEGENERATION; NEUROIMAGING; NEUROPSYCHIATRIC INVENTORY; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PROGRESSIVE LOGOPENIC APHASIA; PROGRESSIVE NONFLUENT APHASIA; SEMANTIC DEMENTIA; TEMPORAL CORTEX;

ADULT; AGED; AGED, 80 AND OVER; APHASIA; COGNITION DISORDERS; DEMENTIA; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 55749085637     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awn234     Document Type: Article

References (39)

1. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003; 289: 2819-26.
2. Boxer AL, Boeve BF. Frontotemporal Dementia Treatment: Current Symptomatic Therapies and Implications of Recent Genetic, Biochemical, and Neuroimaging Studies. Alzheimer Dis Assoc Disord 2007; 21: S79-87.
3. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-14.
4. Deakin JB, Rahman S, Nestor PJ, Hodges JR, Sahakian BJ. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology (Berl) 2004; 172: 400-8.
5. Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test. 2nd edn. San Antonio, TX: The Psychological Crop; 2000.
6. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
7. Forman MS, Farmer J, Johnson JK, Clark CM, Arnold SE, Coslett HB, et al. Frontotemporal dementia: Clinicopathological correlations. Ann Neurol 2006; 59: 952-62.
8. Galton CJ, Patterson K, Xuereb JH, Hodges JR. Atypical and typical presentations of Alzheimer's disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases. Brain 2000; 123: 484-98.
9. Goodglass H, Kaplan E. The assessment of aphasia and related disorders. 2nd edn. Philadelphia: Lea & Febiger; 1983.
10. Gorno-Tempini ML, Dronkers NF, Rankin KP, Ogar JM, Phengrasamy L, Rosen HJ, et al. Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol 2004; 55: 335-46.
11. Grossman M, Xie SX, Libon DJ, Wang X, Massimo L, Moore P, et al. Longitudinal decline in autopsy-defined frontotemporal lobar degeneration. Neurology 2008; 70: 2036-45.
12. Hodges JR, Davies RR, Xuereb JH, Casey B, Broe M, Bak TH, et al. Clinicopathological correlates in frontotemporal dementia. Ann Neurol 2004; 56: 399-406.
13. Hodges JR, Patterson K, Ward R, Garrard P, Bak T, Perry R, et al. The differentiation of semantic dementia and frontal lobe dementia (temporal and frontal variants of frontotemporal dementia) from early Alzheimer's disease: a comparative neuropsychological study. Neuropsychology 1999; 13: 31-40.
14. Hu WT, Mandrekar JN, Parisi JE, Knopman DS, Boeve BF, Petersen RC, et al. Clinical features of pathologic subtypes of behavioral - variant frontotemporal dementia. Arch Neurol 2007; 64: 1611-6.
15. Josephs KA, Duffy JR, Strand EA, Whitwell JL, Layton KF, Parisi JE, et al. Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain 2006; 129: 1385-98.
16. Josephs KA, Whitwell JL, Duffy JR, Vanvoorst WA, Strand EA, Hu WT, et al. Progressive aphasia secondary to Alzheimer disease vs FTLD pathology. Neurology 2008; 70: 25-34.
17. Kaplan E, Goodglass H, Weintraub S. The Boston Naming Test. 2nd edn. Boston: Lea & Fabiger; 1978.
18. Kertesz A, Davidson W, Fox H. Frontal behavioral inventory: diagnostic criteria for frontal lobe dementia. Can J Neurol Sci 1997; 24: 29-36.
19. Kertesz A, McMonagle P, Blair M, Davidson W, Munoz DG. The evolution and pathology of frontotemporal dementia. Brain 2005; 128: 1996-2005.
20. Kertesz A, Nadkarni N, Davidson W, Thomas AW. The Frontal Behavioral Inventory in the differential diagnosis of frontotemporal dementia. J Int Neuropsychol Soc 2000; 6: 460-8.
21. Kipps CM, Nestor PJ, Dawson CE, Mitchell J, Hodges JR. Measuring progression in frontotemporal dementia: Implications for therapeutic interventions. Neurology 2008; 70: 2046-52.
22. Knibb JA, Xuereb JH, Patterson K, Hodges JR. Clinical and pathological characterization of progressive aphasia. Ann Neurol 2006; 59: 156-65.
23. Knopman D, Boeve B, Caselli R, Graff-Radford NR, Kramer JH, Mendez MF, et al. Longitudinal Tracking of FTLD. Toward developing Clinical Trial Methodology. Alzheimer Dis Assoc Disord 2007; 21: S58-63.
24. Kramer JH, Jurik J, Sha SJ, Rankin KP, Rosen HJ, Johnson JK, et al. Distinctive neuropsychological patterns in frontotemporal dementia, semantic dementia, and Alzheimer disease. Cogn Behav Neurol 2003; 16: 211-8.
25. Libon DJ, Xie SX, Moore P, Farmer J, Antani S, McCawley G, et al. Patterns of neuropsychological impairment in frontotemporal dementia. Neurology 2007; 68: 369-75.
26. Mesulam M, Wicklund A, Johnson N, Rogalski E, Leger GC, Rademaker A, et al. Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. Ann Neurol 2008; 63: 709-17.
27. Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11 (Suppl 2): S13-21.
28. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412-4.
29. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998; 51: 1546-54.
30. Perry RJ, Hodges JR. Differentiating frontal and temporal variant frontotemporal dementia from Alzheimer's disease. Neurology 2000; 54: 2277-84.
31. Pfeffer RI, Kurosaki TT, Harrah CH, Jr., Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol 1982; 37: 323-9.
32. Rascovsky K, Salmon DP, Ho GJ, Galasko D, Peavy GM, Hansen LA, et al. Cognitive profiles differ in autopsy-confirmed frontotemporal dementia and AD. Neurology 2002; 58: 1801-8.
33. Rascovsky K, Salmon DP, Lipton AM, Leverenz JB, DeCarli C, Jagust WJ, et al. Rate of progression differs in frontotemporal dementia and Alzheimer disease. Neurology 2005; 65: 397-403.
34. Reitan R. Validity of the Trail-making test as an indication of organic brain damage. Percept Motor Skills 1958; 8: 271-6.
35. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50: 136-45.
36. Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11 (Suppl 2): S22-32.
37. Wechsler D. Wechsler Adult Intelligence Scale-Revised. New York: Psychological Corporation 1981.
38. Wechsler DA. Wechsler Memory Scale-Revised. New York: Psychological Corporation 1987.
39. Wicklund AH, Rademaker A, Johnson N, Weitner BB, Weintraub S. Rate of Cognitive Change Measured by Neuropsychologic Test Performance in 3 Distinct Dementia Syndromes. Alzheimer Dis Assoc Disord 2007; 21: S70-8.